Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 15: Vascular Diseases & Diabetic Retinopathy III

08:00 - 09:30 | 22 September | Room: Room C2.

Back to Previous

08:00Comparative rural/urban diabetic retinopathy prevalence study using low cost fundus camera
G. Mathur India
08:06Chinese guideline of DME: Background, evidence and limitation
X. Li China
08:12Evaluation of ranibizumab and panretinal laser photocoagulation (PRP) in proliferative diabetic retinopathy (PDR) – 24months observational followup of the PRIDE study
G. Lang Germany
08:18Stay or switch? Continued antiVEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema
C. Busch Germany
08:24The influence of the vitreomacular interface on the response to antiVEGF treatment in branch retinal venous occlusions
L. Malheiro Portugal
08:30A realworld study to monitor patients with diabetic macular edema treated with intravitreal aflibercept: Interim analysis of APOLLON
J. Korobelnik France
08:36The combined laser treatment technology as an alternative to conventional laser treatment of diabetic macular edema
D. Buryakov Russian Federation
08:42Retina of diabetic patients without observed retinal vascular changes: A longitudinal study
S. Crisostomo Portugal
08:48Retinal vasculature and structural changes by projectionresolved optical coherence tomography angiography in branch retinal vein occlusion
K. Tsuboi Japan
08:54The role of angiopoietin2 inhibitor on retinal pericyte loss reduction
N. Artha Dewi Indonesia
09:00Pragmatism of randomized clinical trials on ranibizumab for the treatment of diabetic macular edema: Impact on clinical outcomes
S. Stewart United Kingdom
09:06PlGF and VEGF changes after intravitreous injections of conbercept in PDR patients
R. Dai China
09:12Intravitreal ranibizumab for branch retinal vein occlusion complicated with macular edema in patients younger than 50 years
A. Arrigo Italy
09:18Predictive factors of better outcomes by monotherapy with an intravitreal dexamethasone implant (ozurdex®) for branch retinal vein occlusion in clinical practice
M. Jimenez Santos Spain
Back to Previous

Sign up to EURETINA


© EURETINA All rights reserved
Loading please wait